3 news items
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
SLGL
28 May 24
, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
SLGL
20 May 24
as reflected in the below income statement. Research and development expenses were $5.3 million compared to $9.4 million
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
SLGL
16 May 24
substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution
- Prev
- 1
- Next